Background: Determinants of one-carbon metabolism, such as folate and vitamin B 12 , have been implicated in cancer development. Previous studies have not provided conclusive evidence for the importance of circulating concentrations of folate and vitamin B 12 in prostate cancer etiology. The aim of the present study was to investigate the relationship between prostate cancer risk and circulating concentrations of folate and vitamin B 12 in a large prospective cohort. Methods: We analyzed circulating concentrations of folate and vitamin B 12 in 869 cases and 1,174 controls, individually matched on center, age, and date of recruitment, nested within the European Prospective Investigation into Cancer and Nutrition cohort. Relative risks (RR) for prostate cancer were estimated using conditional logistic regression models. Results: Overall, no significant associations were observed for circulating concentrations of folate (P trend =
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Introduction
Folate, primarily supplied by cereals and vegetables, has recently attracted increasing attention as a potential cancer-protective agent (1) . Folate is an essential factor in the one-carbon metabolism pathway which is involved in DNA methylation, synthesis, and repair (2) .
In colorectal cancer-the most frequently studied cancer site in relation to one-carbon metabolism-a relatively high folate status has generally been associated with a modestly reduced risk for cancer development in prospective studies (3) . However, the first randomized controlled trial investigating the potential antineoplastic effect of supplementary folic acid in subjects with colorectal adenomas, reported-at the second followup-a 67% increased risk of advanced lesions in the supplementation arm compared with the placebo arm (4). This unexpected result requires confirmation but could support the hypothesis that folic acid possesses a dual modulatory effect on neoplasia depending on the timing of exposure (5) .
In the one-carbon metabolism pathway, methyl groups are donated by 5-methylenetetrahydrofolate, the predominant form of folate in the circulation, when homocysteine is converted to methionine. This reaction is catalyzed by vitamin B 12 . The methionine derivative S-adenosylmethionine is the universal methyl donor for DNA methylation reactions. Patterns of hypomethylation and gene-specific hypermethylation are often observed in tumor tissue (6) . In prostate cancer, hypermethylation of the CpG island sequences of the glutathione S-transferase k gene (GSTP1) have been observed in >90% of tumor tissues. This is the most frequently reported epigenetic change in prostate cancer, suggesting that hypermethylation may be particularly important in prostate cancer development (7) . High concentrations of folate or vitamin B 12 may therefore increase prostate cancer risk by inducing hypermethylation, even though evidence for this is sparse to date (1) .
In addition to its central role in methylation, folate in the form of 5,10-methyltetrahydrofolate may have a protective role in cancer development by promoting the synthesis of thymidylate from uracil, minimizing the misincorporation of uracil into DNA. Excessive uracil could lead to double-strand breaks and possibly to cancer development (8) .
In studies of prostate cancer, a previous prospective study reported an increased risk associated with elevated circulating concentrations of folate and vitamin B 12 (9) . This association was particularly strong for vitamin B 12 with subjects in the highest quartile showing an almost 3-fold increase in risk compared with the bottom quartile. The study also reported a risk increase for elevated concentrations of folate, but this association disappeared after adjusting for vitamin B 12 concentrations. In addition, a statistically significant increase in prostate cancer risk was observed in the folate supplementation arm of the randomized controlled folate trial, although the numbers were small (4). Only one additional prospective study has been conducted on prostate cancer in relation to plasma folate and vitamin B 12 , and this study reported null results for both circulating folate and vitamin B 12 (10 (11) .
The aim of the present study was to investigate variations in circulating concentrations of folate and vitamin B 12 in relation to prostate cancer risk. The study was conducted within the European Prospective Investigation into Cancer and Nutrition study, using a nested case-control design including 869 prostate cancer cases and 1,174 individually matched controls.
Materials and Methods
Study Cohort. European Prospective Investigation into Cancer and Nutrition study recruitment procedures and collection of questionnaire data, anthropometric measurements, and blood samples have been described in detail elsewhere (12) . In brief, standardized questionnaire data on dietary and nondietary variables were collected between 1992 and 2006 from 519,978 individuals across Europe, including 153,457 men of whom 137,001 provided a blood sample. The present study included prostate cancer cases diagnosed after blood collection and matched control subjects from 7 of the 10 participating countries: Germany, Greece, Italy, the Netherlands, Spain, Sweden, and the United Kingdom. France and Norway were not included in the present study because these cohorts only included women, and Denmark was not included because serum was not available in the Danish cohorts.
Blood samples were collected according to a standardized protocol. Filled syringes were kept at 5jC to 10jC, protected from light, and transferred to a local laboratory for further processing and aliquoting, with the exception of subjects recruited through the Oxford center. Here, blood samples were collected throughout the United Kingdom and transported to a laboratory in Norfolk by mail at ambient temperature. Blood fractions (serum, plasma, red cells, and buffy coat) were aliquoted into 0.5 mL straws, which were then heat-sealed and stored in liquid nitrogen tanks at À196jC, except in Umeå Sweden, where samples were stored in 1.8 mL plastic tubes in À80jC freezers.
Follow-up for Cancer Incidence and Vital Status. In Italy, the Netherlands, Spain, Sweden, and the United Kingdom, incident cancer cases were identified through record linkage with regional or national cancer registries. In Germany and Greece, follow-up was based on a combination of methods, including health insurance records, cancer and pathology registries, and active follow-up through study subjects and their next-of-kin. Data on vital status in most European Prospective Investigation into Cancer and Nutrition study centers were collected from mortality registries at the regional or national level, in combination with data collected by active follow-up (Greece). For each European Prospective Investigation into Cancer and Nutrition study center, closure dates of the study period were defined as the latest dates of complete follow-up for both cancer incidence and vital status (dates varied between centers, from June 1999 to January 2006).
Selection of Case and Control Subjects. In total, the seven subcohorts contributing to the present study Cases with no available blood sample and those who had missing information on the date of blood donation or who had a history of another cancer (except nonmelanoma skin cancer) at the time of blood donation were excluded. After these exclusions, laboratory measurements for the current analysis were available for 1,107 cases: 61 cases in Italy, 182 in Germany, 9 in Greece, 24 in the Netherlands, 94 in Spain, 560 in Sweden, and 177 in the United Kingdom. For each case, one male control (two in Umeå) was chosen at random from appropriate risk sets consisting of all cohort members alive and free of cancer (except nonmelanoma skin cancer) at the time of diagnosis of the index case. Matching criteria were study center, age at enrollment (F6 months), time of day of blood collection (F1 h), and time between blood draw and last consumption of food or drink (<3, 3-6, >6 h). Two hundred and thirty-eight cases from the Swedish cohort had been used in a previous study on the relation between prostate cancer and circulating concentrations of folate and vitamin B 12 (9) .
These subjects and their matched controls were therefore excluded from the main data analysis of the present study. In total, 869 cases and 1,174 controls were included in the present study. All participants gave written informed consent to participate in the study and the research was approved by the local ethics committees in the participating countries and the Internal Review Board of the IARC.
Data on stage and grade of disease were collected from each center where possible. Tumor stage was categorized as localized (tumor-node-metastasis categories T 0 or T 1 or T 2 , and N 0 or N X , and M 0 , or stage coded in the recruitment center as localized), advanced (T 3 or T 4 and/or N 1+ and/or M 1 , or stage coded in the recruitment center as metastatic), or unknown. Histologic grade was categorized as Gleason sum <7 or equivalent (tumors coded as well-differentiated or moderately differentiated), Gleason sum z7 or equivalent (tumors coded as poorly differentiated or undifferentiated), or unknown.
Biochemical Analyses. Cases were analyzed in the same batch as their matched controls. All assays were done by laboratory personnel who were blinded as to the case-control status of the blood samples. Folate concentrations were determined by a Lactobacillus casei microbiological assay (13) and vitamin B 12 concentrations were determined by a Lactobacillus leichmannii microbiological assay (14, 15) . Both folate and vitamin B 12 assays were adapted to a microtiter plate format and carried out by a robotic workstation (Microlab AT plus 2; Hamilton Bonaduz). The within-and between-run variations were 6.0% and 6.3%, respectively, for folate, and 5.4% and 6.7%, respectively, for vitamin B 12 .
Statistical Analyses. Circulating concentrations of folate and vitamin B 12 were categorized into quintiles ; in quartiles), physical activity (index of combined recreational, household, and occupational physical activity: inactive, moderately inactive, and active), marital status (married/cohabiting, not married/cohabiting), and education level (primary school or none, secondary school or equivalent, university degree). For each of these variables, a small proportion of values were unknown, and these were included in the analyses as unknown categories. m 2 tests were used to examine heterogeneity between subgroups in the association of prostate cancer risk with concentrations of folate and vitamin B 12 . All P values presented are two-sided and P < 0.05 was considered statistically significant. Statistical analyses were done using Statistical Analysis System software (SAS Institute).
Results
Baseline Characteristics. Baseline characteristics of cases and controls are shown in Table 1 . Overall, we observed no major differences in characteristics between cases and controls. The median age at blood collection was 59.1 years for cases and 58.3 years for controls. Cases were less likely to smoke, less physically active, and had a lower body weight than the controls.
The median time between blood collection and case diagnosis was 5 years. Stage of disease was known for 60.5% of the cases, of which 30.6% were classified as having advanced disease. Grade of disease was known for 83.5% of cases, of which 34.4% were classified as having high-grade disease.
Median concentrations of folate and vitamin B 12 by country and case-control status are shown in Table 2 . Folate concentrations differed substantially between the countries, with Sweden having low concentrations (median, 5.6 nmol/L in controls) and Germany and the Table 3 . There were no significant associations with overall risk for circulating concentrations of folate or vitamin B 12 in unadjusted or adjusted logistic regression, as determined by the trend test, although an increase in risk was observed in the fourth folate quintile compared with the lowest quintile. Because the Swedish subjects displayed very low folate concentrations, we also did a logistic regression with the quintiles for the Swedish and nonSwedish subjects defined separately (see Table 4 ). In these analyses, no association between concentrations of folate and prostate cancer risk were observed for any quintile or for overall trend.
Relative risks associated with a doubling of folate and vitamin B 12 concentrations for selected subgroups are shown in Tables 5 and 6 . We investigated heterogeneity between subgroups defined by tumor stage (localized or advanced), histologic grade (low or high), lag time between blood collection and diagnosis (<4 or z4 years), age at diagnosis (<65 or z65 years), and country of recruitment (seven countries). For circulating concentrations of folate, no significant heterogeneity between subgroups was observed for any of these factors. For circulating concentrations of vitamin B 12 We also separately analyzed the subjects used in the previous Swedish study that were excluded from the analyses described above (9) . These subjects were reanalyzed using the same biochemical assay as all other subjects in the present study. This analysis resulted in a highly significant association for vitamin B 12 in relation to prostate cancer risk (trend RR, 1.83; 95% CI, 1.29-2.61, P = 0.0008), as reported in the original study.
Discussion
In this study, the largest prospective study investigating circulating concentrations of folate and vitamin B 12 in relation to prostate cancer risk to date, we observed no 12 showing a significant association with increased risk of advanced stage prostate cancer, whereas no association was observed among the localized stage cases.
To date, most studies on the relationship between factors of one-carbon metabolism and human cancer have been conducted on colorectal cancer, and prospective studies have generally supported the hypothesis of a protective effect of elevated concentrations of folate in the circulation (3) . Recently, however, this association has been questioned in the light of a randomized controlled trial investigating the potential antineoplastic effect of supplementary folate in subjects with colorectal adenomas (4) . At the second follow-up of this trial, Cole et al. reported a 67% increased risk of advanced lesions in the supplementation arm compared with the placebo arm (4). This surprising result, together with animal studies showing the antineoplastic effects of folate on normal epithelial tissue and-in contrast-a promoting effect on established neoplasms, has led to the hypothesis of a dual effect of folate on cancer development. The effect of elevated concentrations of folate would depend on the timing of exposure, i.e., if the exposure is exerted before or after neoplastic transformations (16 (10) . However, it should be noted that subjects in this study were all heavy smokers, and therefore, the cohort may not be representative of the overall population. In the present study, we did not have enough power to assess smoking as a potential effect modifier. In 2005, Hultdin et al. reported a significant increase in prostate cancer risk for elevated concentrations of vitamin B 12 , and a positive association of folate with risk, although the latter association disappeared after adjusting for vitamin B 12 concentration (9). We reanalyzed 94% of the cases included in that study using the same assay as in the present study, and the association between vitamin B 12 and risk among these subjects remained highly significant. These subjects were excluded from the main analysis of the present study because we anticipated that they would influence the overall result. In the present study, no significant associations were observed for concentrations of folate or vitamin B 12 with prostate cancer risk overall, however, we observed a significant increase in risk for subjects in the fourth folate quintile. Because the Swedish samples displayed very low concentrations of folate compared with the other countries, we did analyses stratified by Swedish and non-Swedish subjects and, in these analyses, no association was observed overall or for any individual quintile. The only statistically significant trend association with prostate cancer risk in the present study was observed in the group of men diagnosed with advanced stage disease. In this subgroup, a doubling in vitamin B 12 concentration was associated with a 69% increase in prostate cancer risk. We could not compare this association with the previous studies because neither of them reported results by stage of disease (9, 10) . The reason for the association between advanced stage prostate cancer and vitamin B 12 is unknown; speculatively, it may be related to advanced cases being phenotypically less similar to controls compared with the group of localized cases that might be diluted with clinically less relevant cases. Alternatively, the association might be due to chance. In subgroup analyses by participating countries, the Swedish subjects displayed no association between vitamin B 12 and prostate cancer risk. This contrasts with the strong association between elevated vitamin B 12 concentrations and increased prostate cancer risk noted in the previous study from the same subcohort of subjects not included in this study (9) . The reason for this apparent change in the association in Sweden is not known, but it could be due to differences in the characteristics of the cases, or that the association noted in the previous study was due to chance.
One particular feature of the present study was the large differences in folate concentrations observed across the participating countries. The participants in Germany and United Kingdom displayed almost three times the median folate concentrations of Sweden. The reasons for these large differences are not known, but are presumably related to differences between study centers in the dietary intake of folate and in sample handling. Folate, in contrast to vitamin B 12 , is degraded during storage, and time between blood draw and freezing of the samples varied between the centers (17) . In addition, in Väst-erbotten County, where the Swedish samples were collected, low intake of vegetables has previously been reported which may partly explain the low folate concentrations observed among the Swedish participants (18) . It should also be noted that the Swedish samples were plasma and that samples from all the other countries were serum, but this difference between the cohorts would not be expected to result in such large differences in folate concentrations. Overall, the study design of controls individually matched to cases by center, age, and date of blood draw effectively controls for any systematic differences between countries when estimating the overall trends.
Given that prostate cancer is a slowly developing disease with neoplastic transformation occurring many years before diagnosis (7), the direction of the relative risks of folate estimated in prospective studies might depend on time between blood draw and diagnosis (lag time). Even though no heterogeneity in relative risks was observed for folate or for vitamin B 12 when stratifying on lag-time in the present study, few cases had a lag time of >10 years. It might be useful to investigate prospectively collected prostate cancer samples with very long lag-time in order to assess the potentially complex nature of onecarbon metabolism and prostate cancer (19) . Because a single plasma or serum sample only provides an estimate of folate/vitamin B 12 exposure over the previous days, it would also be useful to study samples from each subject obtained at several time points in order to estimate longterm exposure.
In conclusion, this study does not provide support for the hypothesis that circulating concentrations of folate or vitamin B 12 are related to prostate cancer risk. Further prospective studies are needed to investigate the possible association between high concentrations of vitamin B 12 and increased risk of advanced stage prostate cancer.
